RIGL (Rigel Pharmaceuticals) Receipts from Government Grants


RIGL Rigel Pharmaceuticals Inc RIGL
78 GF Score
Price $36.75
GF Value $28.34
Valuation Modestly Overvalued
! 8 Warning Signs
View Full Analysis

What is Rigel Pharmaceuticals Receipts from Government Grants?

Receipts from Government Grants only applicable to companies reporting Cash Flow from Operations in direct method.

RIGL
78GF Score
Rigel Pharmaceuticals Inc RIGL
Receipts from Government Grants is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Rigel Pharmaceuticals (RIGL) Overvalued in 2026?

Based on GuruFocus' analysis, Rigel Pharmaceuticals stock appears to be overvalued. The current stock price of $36.75 is trading 29.7% above its estimated GF Value™ of $28.34. GuruFocus considers Rigel Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for RIGL:

  • Receipts from Government Grants:
  • GF Value™: $28.34 vs. price of $36.75 (29.7% above fair value)
  • GF Score™: 78/100 with 8 warning signs

No single metric tells the full story. See the RIGL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Rigel Pharmaceuticals Business Description

Address 611 Gateway Boulevard, Suite 900, South San Francisco, CA, USA, 94080
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
78GF Score

Get the complete analysis for RIGL

Receipts from Government Grants is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$36.75
Price
$28.34
GF Value